Hims & Hers Health, Inc. (HIMS)
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hims & Hers: The Gift That Keeps On Giving
Hims & Hers stock is currently in the middle of a deep drawdown, with HIMS stock nearly 35% off of its recent highs. However, the telehealth platform company remains a fundamentally sound business and is getting stronger by broadening its diversified weight loss offering through the addition of compounded GLP-1s. As of Q2, Hims & Hers is delivering top-line hypergrowth, and turning into an FCF machine.
Hims & Hers Is Unbelievably Cheap And Profitable: Buy Now
Hims & Hers is a fantastic value despite its high 'on-the-surface' P/E ratio and valuation metrics. The company's subscription-based model in healthcare, targeting chronic conditions, ensures recurring revenue and high customer retention, leading to consistent revenue growth. High gross margins lead to incredible operating leverage, and we see net income increasing from $15 million to more than $600 million in the next 24 months.
Hims & Hers Health, Inc. (HIMS) Rises Higher Than Market: Key Facts
The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $16.44, representing a +0.86% change from its previous close.
Hims & Hers offers compounded Wegovy for $99 a month to select professions
U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular weight-loss drug Wegovy to patients in certain professions for $99 a month.
Hims & Hers Acquisition: How Innovation Will Flourish
Buying a new pharmacy will allow Hims & Hers to expand into new markets.
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
This telemedicine company seems to leapfrog from one hot area in healthcare to another. Its strategy of acquiring members and turning them into paid subscribers is promising.
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $16.28, moving -1.75% from the previous trading session.
Hims & Hers Stock Pops After Massive Acquisition
Hims & Hers completed the acquisition of MedisourceRX, a pharmacy that will expand in-house production. The deal included issuing stock, which will ultimately dilute shareholders.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hims & Hers Health Stock Is Crashing: Should You Buy the Dip?
Hims & Hers' business grew by more than 50% last quarter. The company has plenty more growth opportunities to pursue in pain management, fertility, and diabetes.
Is Hims & Hers Health the Next Teladoc?
Demand for telemedicine services boomed during the pandemic lockdowns. Teladoc stock price soared more than 250%, only to plunge.
